QFracture — 10-Year Osteoporotic Fracture Risk
Approximates QFracture-2016 10-year risk of major osteoporotic fracture (hip / spine / wrist / shoulder). NICE NG28 endorses QFracture (alongside FRAX) for adults 30–99 yr without prior osteoporosis treatment. Uses additive risk weights — for the formal logistic model use the official ClinRisk tool.
Score interpretation
→ Lifestyle advice: weight-bearing exercise, calcium 700–1200 mg/d, vitamin D 800 IU/d if at risk. Re-assess in 5 years.
→ Arrange DEXA per NICE NG28. Treat if T-score ≤ −2.5 or per FRAX/NOGG thresholds.
→ Treat without DEXA in selected groups (e.g. age >75 with hip fracture). Otherwise DEXA + bisphosphonate (alendronate first-line); zoledronate or denosumab if oral intolerance; calcium/vitamin D; falls prevention.
Interpretation bands for the QFracture. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Denosumab · Anti-RANKL Monoclonal Antibody
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Alendronic Acid (Alendronate) · Bisphosphonate (bone resorption inhibitor)
- Zoledronic Acid · IV Bisphosphonate
- Ciprofloxacin with dexamethasone · Topical otic antibiotic + corticosteroid
- Zoledronic Acid · Bisphosphonate
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.